IDEAS home Printed from https://ideas.repec.org/f/pde716.html
   My authors  Follow this author

Olivier de Mouzon

Personal Details

First Name:Olivier
Middle Name:
Last Name:de Mouzon
Suffix:
RePEc Short-ID:pde716
[This author has chosen not to make the email address public]

Affiliation

Toulouse School of Economics (TSE)

Toulouse, France
http://www.tse-fr.eu/
RePEc:edi:tsetofr (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Laurent, Thibault & Le Breton, Michel & Lepelley, Dominique & de Mouzon, Olivier, 2017. "Exploring the Effects on the Electoral College of National and Regional Popular Vote Interstate Compact: An Electoral Engineering Perspective," TSE Working Papers 17-861, Toulouse School of Economics (TSE), revised May 2018.
  2. Laurent, Thibault & Le Breton, Michel & Lepelley, Dominique & de Mouzon, Olivier, 2016. "The Theoretical Shapley-Shubik Probability of an Election Inversion in a Toy Symmetric Version of the U.S. Presidential Electoral System," TSE Working Papers 16-671, Toulouse School of Economics (TSE), revised Feb 2018.
  3. Bonnet, Céline & de Mouzon, Olivier, 2014. "Analysis of Multiple Discrete-Continuous Choices: Empirical Evidence of Biased Price Elasticities under Standard Discrete Choice models on the Soft Drink Market," TSE Working Papers 14-520, Toulouse School of Economics (TSE).
  4. Bonnet, Céline & de Mouzon, Olivier, 2011. "An Analysis of Taste Variety within Households on Soft Drinks," 2011 International Congress, August 30-September 2, 2011, Zurich, Switzerland 114261, European Association of Agricultural Economists.
  5. Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
  6. Dallongeville, Jean & Dauchet, Luc & de Mouzon, Olivier & Réquillart, Vincent & Soler, Louis-Georges, 2010. "Are Fruit and Vegetable Stamp Policies Cost Effective?," IDEI Working Papers 648, Institut d'Économie Industrielle (IDEI), Toulouse.
  7. Dallongeville, Jean & Dauchet, Luc & de Mouzon, Olivier & Réquillart, Vincent & Soler, Louis-Georges, 2009. "Increasing Fruits and Vegetables Consumption: A Cost-Efficiency Analysis of Public Policies," IDEI Working Papers 554, Institut d'Économie Industrielle (IDEI), Toulouse.

Articles

  1. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
  2. O. de Mouzon & V. Réquillart & L.-G. Soler & J. Dallongeville & L. Dauchet, 2012. "Are fruit and vegetable voucher policies cost-effective?," European Review of Agricultural Economics, Oxford University Press and the European Agricultural and Applied Economics Publications Foundation, vol. 39(5), pages 771-795, December.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.

    Mentioned in:

    1. What’s at stake if U.S. drug prices fall?
      by Jason Shafrin in Healthcare Economist on 2018-02-02 06:14:36

Working papers

  1. Laurent, Thibault & Le Breton, Michel & Lepelley, Dominique & de Mouzon, Olivier, 2017. "Exploring the Effects on the Electoral College of National and Regional Popular Vote Interstate Compact: An Electoral Engineering Perspective," TSE Working Papers 17-861, Toulouse School of Economics (TSE), revised May 2018.

    Cited by:

    1. Elizabeth Maggie Penn, 2019. "Introduction to a special issue in honor of Kenneth Arrow," Public Choice, Springer, vol. 179(1), pages 1-6, April.
    2. de Mouzon, Olivier & Laurent, Thibault & Le Breton, Michel & Moyouwou, Issofa, 2020. "“One Man, One Vote” Part 1: Electoral Justice in the U.S. Electoral College: Banzhaf and Shapley/Shubik versus May," TSE Working Papers 20-1074, Toulouse School of Economics (TSE).

  2. Laurent, Thibault & Le Breton, Michel & Lepelley, Dominique & de Mouzon, Olivier, 2016. "The Theoretical Shapley-Shubik Probability of an Election Inversion in a Toy Symmetric Version of the U.S. Presidential Electoral System," TSE Working Papers 16-671, Toulouse School of Economics (TSE), revised Feb 2018.

    Cited by:

    1. Laurent, Thibault & Le Breton, Michel & Lepelley, Dominique & de Mouzon, Olivier, 2017. "Exploring the Effects on the Electoral College of National and Regional Popular Vote Interstate Compact: An Electoral Engineering Perspective," TSE Working Papers 17-861, Toulouse School of Economics (TSE), revised May 2018.
    2. Olivier Mouzon & Thibault Laurent & Michel Breton & Dominique Lepelley, 2019. "Exploring the effects of national and regional popular vote Interstate compact on a toy symmetric version of the Electoral College: an electoral engineering perspective," Public Choice, Springer, vol. 179(1), pages 51-95, April.
    3. Michael Geruso & Dean Spears & Ishaana Talesara, 2019. "Inversions in US Presidential Elections: 1836-2016," NBER Working Papers 26247, National Bureau of Economic Research, Inc.
    4. Serguei Kaniovski & Alexander Zaigraev, 2018. "The probability of majority inversion in a two-stage voting system with three states," Theory and Decision, Springer, vol. 84(4), pages 525-546, June.
    5. Kazuya Kikuchi, 2022. "Welfare ordering of voting weight allocations," Papers 2208.05316, arXiv.org, revised Mar 2024.
    6. de Mouzon, Olivier & Laurent, Thibault & Le Breton, Michel & Moyouwou, Issofa, 2020. "“One Man, One Vote” Part 1: Electoral Justice in the U.S. Electoral College: Banzhaf and Shapley/Shubik versus May," TSE Working Papers 20-1074, Toulouse School of Economics (TSE).

  3. Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.

    Cited by:

    1. Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," LEM Papers Series 2021/37, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    2. Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
    3. Kortelainen, Mika & Markkanen, Jaakko & Toivanen, Otto & Siikanen, Markku, 2023. "The Effects of Price Regulation on Pharmaceutical Expenditure and Availability," CEPR Discussion Papers 18497, C.E.P.R. Discussion Papers.
    4. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
    5. Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
    6. Iain M. Cockburn & Jean O. Lanjouw & Mark Schankerman, 2014. "Patents and the Global Diffusion of New Drugs," NBER Working Papers 20492, National Bureau of Economic Research, Inc.
    7. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    8. Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
    9. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    10. Kazuhiro Takauchi & Tomomichi Mizuno, 2019. "Consumer-benefiting transport cost: The role of product innovation in a vertical structure," Discussion Papers 1911, Graduate School of Economics, Kobe University.
    11. Matthew J. Higgins & Mathias J. Kronlund & Ji Min Park & Joshua Pollet, 2020. "The Role of Assets In Place: Loss of Market Exclusivity and Investment," NBER Working Papers 27588, National Bureau of Economic Research, Inc.
    12. Mehmet Ugur & Eshref Trushin, 2023. "Information asymmetry, risk aversion and R&D subsidies: effect-size heterogeneity and policy conundrums," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 32(8), pages 1190-1215, November.
    13. Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148462, HAL.
    14. Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
    15. Jeffrey Clemens, 2013. "The Effect of U.S. Health Insurance Expansions on Medical Innovation," NBER Working Papers 19761, National Bureau of Economic Research, Inc.
    16. Heidi L. Williams, 2016. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
    17. Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2021. "Innovation And Diffusion Of Medical Treatment," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 62(3), pages 953-1009, August.
    18. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
    19. Asher Curtis & Sarah McVay & Sara Toynbee, 2020. "The changing implications of research and development expenditures for future profitability," Review of Accounting Studies, Springer, vol. 25(2), pages 405-437, June.
    20. Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
    21. Jeffrey Clemens & Parker Rogers, 2020. "Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents," NBER Working Papers 26679, National Bureau of Economic Research, Inc.
    22. Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
    23. Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2018. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 115-157, National Bureau of Economic Research, Inc.
    24. Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
    25. Liu, Qing & Ma, Hong, 2020. "Trade policy uncertainty and innovation: Firm level evidence from China’s WTO accession," Journal of International Economics, Elsevier, vol. 127(C).
    26. Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
    27. Iizuka, Toshiaki & Uchida, Gyo, 2017. "Promoting innovation in small markets: Evidence from the market for rare and intractable diseases," Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
    28. Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
    29. Civelek Mehmet & Červinka Michal & Gajdka Krzysztof & Nétek Václav, 2021. "Marketing communication tools and their influence on marketing innovation: Evidence from Slovakian SMEs," Management & Marketing, Sciendo, vol. 16(3), pages 210-227, September.
    30. Dubois, P.; & Majewska, G.; & Reig, V.;, 2023. "Drug Shortages: Empirical Evidence from France," Health, Econometrics and Data Group (HEDG) Working Papers 23/07, HEDG, c/o Department of Economics, University of York.
    31. Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers 24957, National Bureau of Economic Research, Inc.
    32. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
    33. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    34. David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
    35. Frankovic, Ivan & Kuhn, Michael, 2023. "Health insurance, endogenous medical progress, health expenditure growth, and welfare," Journal of Health Economics, Elsevier, vol. 87(C).
    36. Kalcheva, Ivalina & McLemore, Ping & Pant, Shagun, 2018. "Innovation: The interplay between demand-side shock and supply-side environment," Research Policy, Elsevier, vol. 47(2), pages 440-461.
    37. Frank, Richard G. & Zeckhauser, Richard J., 2018. "Excess Prices for Drugs in Medicare: Diagnosis and Prescription," Working Paper Series rwp18-005, Harvard University, John F. Kennedy School of Government.
    38. Dubois, Pierre & Gentry, Elissa & Tuncel, Tuba, 2023. "Strategic Submissions: A Cross-Country Analysis of Supplemental Drug Approvals," TSE Working Papers 23-1459, Toulouse School of Economics (TSE), revised Aug 2024.
    39. Schwardmann, Peter, 2017. "Motivated Health Risk Denial and Preventative Health Care Investments," Rationality and Competition Discussion Paper Series 33, CRC TRR 190 Rationality and Competition.
    40. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    41. Ugur, Mehmet & Trushin, Eshref, 2018. "Asymmetric information and heterogeneous effects of R&D subsidies: evidence on R&D investment and employment of R&D personel," Greenwich Papers in Political Economy 21943, University of Greenwich, Greenwich Political Economy Research Centre.
    42. Dubois, Pierre & Majewska, Gosia, 2022. "Mergers and Advertising in the Pharmaceutical Industry," TSE Working Papers 22-1380, Toulouse School of Economics (TSE).
    43. Leona Shao-Zhi Li & Yize Liu & Jia Yuan, 2024. "The effect of the U.S.–China trade war on Chinese corporate innovation: A curse or a blessing?," Working Papers 202418, University of Macau, Faculty of Business Administration.
    44. Branstetter, Lee G. & Kwon, Namho, 2018. "South Korea's transition from imitator to innovator: The role of external demand shocks," Journal of the Japanese and International Economies, Elsevier, vol. 49(C), pages 28-42.
    45. David Dranove & Craig Garthwaite & Manuel Hermosilla, 2014. "Pharmaceutical Profits and the Social Value of Innovation," NBER Working Papers 20212, National Bureau of Economic Research, Inc.
    46. Lemarié, Stéphane & Parenty, Sébastien, 2016. "Research incentives and tradeoff for improving productivity of different crops," 149th Seminar, October 27-28, 2016, Rennes, France 245161, European Association of Agricultural Economists.
    47. Arzi Adbi & Chirantan Chatterjee & Matej Drev & Anant Mishra, 2019. "When the Big One Came: A Natural Experiment on Demand Shock and Market Structure in India's Influenza Vaccine Markets," Production and Operations Management, Production and Operations Management Society, vol. 28(4), pages 810-832, April.
    48. Aline Fugeray-Scarbel & Stéphane Lemarié, 2024. "The amplified effect of market size on innovation: A comparative analysis of pea and wheat seed value chains in France," Post-Print hal-04631965, HAL.
    49. Mujaheed Shaikh & Pietro Giudice & Dimitrios Kourouklis, 2021. "Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 217-229, March.
    50. Dubois, Pierre & Majewska, Gosia & Reig, Valentina, 2023. "Drug Shortages: Empirical Evidence from France," TSE Working Papers 23-1417, Toulouse School of Economics (TSE).
    51. Margaret K. Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
    52. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
    53. Dubois, Pierre & Moisson, Paul-Henri & Tirole, Jean, 2022. "The Economics of Transferable Patent Extensions," TSE Working Papers 22-1377, Toulouse School of Economics (TSE), revised Dec 2022.
    54. Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
    55. Agarwal, Ruchir & Gaule, Patrick, 2022. "What drives innovation? Lessons from COVID-19 R&D," Journal of Health Economics, Elsevier, vol. 82(C).
    56. Jeffrey P. Clemens & Morten Olsen, 2021. "Medicare and the Rise of American Medical Patenting: The Economics of User-Driven Innovation," CESifo Working Paper Series 9008, CESifo.
    57. Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.
    58. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    59. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    60. Mayank Aggarwal & Anindya Chakrabarti & Chirantan Chatterjee & Matthew J. Higgins, 2021. "Research and Market Structure: Evidence from an Antibiotic-Resistant Pathogenic Outbreak," NBER Working Papers 28840, National Bureau of Economic Research, Inc.
    61. Andreas Beerli & Franziska J. Weiss & Fabrizio Zilibotti, 2018. "Demand forces of technical change: evidence from the Chinese manufacturing industry," ECON - Working Papers 277, Department of Economics - University of Zurich.
    62. Anirban Basu, 2024. "Dynamic Efficiency and Pricing of Innovations with Insurance: The Case for Gene Therapies," NBER Working Papers 32480, National Bureau of Economic Research, Inc.
    63. Federico Nutarelli & Massimo Riccaboni & Andrea Morescalchi, 2021. "Product recalls, market size and innovation in the pharmaceutical industry," Papers 2111.15389, arXiv.org.
    64. Geng, Hao & Shi, Ce Matthew, 2024. "Health policy, price regulation, and innovation: Evidence from China’s vaccine industry," Journal of Development Economics, Elsevier, vol. 167(C).
    65. Gentilini, Arianna & Miraldo, Marisa, 2023. "The role of patient organisations in research and development: Evidence from rare diseases," Social Science & Medicine, Elsevier, vol. 338(C).
    66. Marek Ignaszak & Petr Sedlacek, 2021. "Profitability, Productivity and Growth," Discussion Papers 2115, Centre for Macroeconomics (CFM).
    67. Yong Tan, 2019. "Dynamic Entry With Demand And Supply Side Spillovers," Contemporary Economic Policy, Western Economic Association International, vol. 37(1), pages 86-101, January.
    68. Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
    69. Marco Sahm, 2020. "Advance-Purchase Financing of Projects with Few Buyers," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 57(4), pages 909-933, December.
    70. Wei Fu & Shin-Yi Chou & Li-San Wang, 2022. "NIH Grant Expansion, Ancestral Diversity and Scientific Discovery in Genomics Research," NBER Working Papers 30155, National Bureau of Economic Research, Inc.
    71. Callejas, Jerónimo & Mohapatra, Debi Prasad, 2021. "Welfare effects of public procurement of medicines: Evidence from Ecuador," International Journal of Industrial Organization, Elsevier, vol. 75(C).
    72. Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
    73. Stern, Ariel Dora, 2017. "Innovation under regulatory uncertainty: Evidence from medical technology," Journal of Public Economics, Elsevier, vol. 145(C), pages 181-200.
    74. Yan Wen & Lu Liu, 2023. "Comparative Study on Low-Carbon Strategy and Government Subsidy Model of Pharmaceutical Supply Chain," Sustainability, MDPI, vol. 15(10), pages 1-26, May.
    75. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
    76. Sahm, Marco, 2016. "Advance-purchase financing of projects with few buyers," BERG Working Paper Series 118, Bamberg University, Bamberg Economic Research Group.
    77. Huvaj, M. Nesij & Johnson, William C., 2019. "Organizational complexity and innovation portfolio decisions: Evidence from a quasi-natural experiment," Journal of Business Research, Elsevier, vol. 98(C), pages 153-165.
    78. Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
    79. Jillian Chown & David Dranove & Craig Garthwaite & Jordan Keener, 2019. "The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada," NBER Working Papers 26122, National Bureau of Economic Research, Inc.
    80. Johnson, Abbie-Gayle & Buhalis, Dimitrios, 2022. "Solidarity during times of crisis through co-creation," Annals of Tourism Research, Elsevier, vol. 97(C).
    81. Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
    82. Wang, Lucy Xiaolu, 2022. "Global drug diffusion and innovation with the medicines patent pool," Journal of Health Economics, Elsevier, vol. 85(C).
    83. Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.

  4. Dallongeville, Jean & Dauchet, Luc & de Mouzon, Olivier & Réquillart, Vincent & Soler, Louis-Georges, 2010. "Are Fruit and Vegetable Stamp Policies Cost Effective?," IDEI Working Papers 648, Institut d'Économie Industrielle (IDEI), Toulouse.

    Cited by:

    1. Irz, Xavier & Leroy, Pascal & Réquillart, Vincent & Soler, Louis-Georges, 2015. "Economic assessment of nutritional recommendations," Journal of Health Economics, Elsevier, vol. 39(C), pages 188-210.

  5. Dallongeville, Jean & Dauchet, Luc & de Mouzon, Olivier & Réquillart, Vincent & Soler, Louis-Georges, 2009. "Increasing Fruits and Vegetables Consumption: A Cost-Efficiency Analysis of Public Policies," IDEI Working Papers 554, Institut d'Économie Industrielle (IDEI), Toulouse.

    Cited by:

    1. Silva, Andres & Etilé, Fabrice & Jamet, Gaelle, 2013. "Consequences of the Five-a-Day Campaign: Evidence from French Panel Data," 2013 Annual Meeting, August 4-6, 2013, Washington, D.C. 150426, Agricultural and Applied Economics Association.
    2. Bonnet, Céline & Réquillart, Vincent, 2013. "Tax incidence with strategic firms in the soft drink market," Journal of Public Economics, Elsevier, vol. 106(C), pages 77-88.
    3. Nicole Darmon & Anne Lacroix & Laurent Muller & Bernard Ruffieux, 2014. "Food price policies improve diet quality while increasing socioeconomic inequalities in nutrition," Post-Print hal-01845621, HAL.
    4. Marie-Violaine Tatry & Dominique Fournier & Benoît Jeannequin & Françoise Dosba, 2014. "EU27 and USA leadership in fruit and vegetable research: a bibliometric study from 2000 to 2009," Scientometrics, Springer;Akadémiai Kiadó, vol. 98(3), pages 2207-2222, March.
    5. Bonnet, Céline & Réquillart, Vincent, 2011. "Strategic Pricing and Health Price Policies," IDEI Working Papers 671, Institut d'Économie Industrielle (IDEI), Toulouse, revised Jul 2012.

Articles

  1. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
    See citations under working paper version above.Sorry, no citations of articles recorded.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 7 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-AGR: Agricultural Economics (2) 2010-12-11 2011-10-15
  2. NEP-COM: Industrial Competition (2) 2011-11-28 2014-11-07
  3. NEP-INO: Innovation (2) 2011-11-28 2011-11-28
  4. NEP-POL: Positive Political Economics (2) 2016-07-30 2018-01-08
  5. NEP-CDM: Collective Decision-Making (1) 2018-01-08
  6. NEP-CSE: Economics of Strategic Management (1) 2011-11-28
  7. NEP-DCM: Discrete Choice Models (1) 2014-11-07
  8. NEP-HEA: Health Economics (1) 2011-11-28
  9. NEP-IND: Industrial Organization (1) 2011-11-28
  10. NEP-IPR: Intellectual Property Rights (1) 2011-11-28
  11. NEP-TID: Technology and Industrial Dynamics (1) 2011-11-28

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Olivier de Mouzon should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.